GlaxoSmithKline adult shingles vaccine wins U.S. approval

Oct 20 (Reuters) - The U.S. Food and Drug Administration approved GlaxoSmithKline's Shingrix shingles vaccine for use in adults aged 50 and over, a move widely expected after an advisory panel to the agency last month voted unanimously to recommend its approval, the company announced on Friday.